Sustained Antiviral Effects and Clearance of Hepatitis Surface Antigen after Combination Therapy with Entecavir and Pegylated Interferon in Chronic Hepatitis B

Abstract

Background

Although the efficacy of combination therapy with lamivudine or tenofovir and pegylated interferon (PEG-IFN) has been reported in patients with chronic hepatitis B (CHB), the long-term effect of the combination based on the observation of clinical course remains to be clarified. We previously reported the efficacy of combination therapy with entecavir (ETV) and PEG-IFN. Here, we investigated the long-term effect of this combination in patients with CHB.

Methods

We administered both ETV and PEG-IFN-α2a or -2b simultaneously to 26 patients with HBV genotype C infection. Treatment was continued for 48 weeks followed by 24 weeks of observation period; we examined the virological and biochemical responses. We also analysed characteristics related to the post-treatment relapse. Finally, we investigated the long-term therapeutic effects.

Results

Average reduction of intra-hepatic cccDNA level was 1.2 log copies/μg at the completion of administration. Pretreatment hepatitis B surface antigen (HBsAg) level with more than 3.5 log U/ml was identified as a predictive factor for relapse. Furthermore, the cumulative rates of HBsAg-negative patients at 1, 3 and 5 years after the completion of administration were 3.8, 8.4 and 15%, respectively (mean follow-up period: 4.8 years).

Conclusions

Baseline HBsAg level with more than 3.5 log U/ml is a useful predictor for relapse 24 weeks after the completion of administration in patients treated with combination therapy. Combination with ETV and PEG-IFN could be an option for treatment of CHB patients especially in those with baseline HBsAg levels of less than 3.5 log U/ml.

References

Summers

, Mason

W.S.

Replication of the genome of a hepatitis B–like virus by reverse transcription of an RNA intermediate.

Cell 1982; 29: 403–415.

Dienstag

J.L.

, Perrillo

R.P.

, Schiff

E.R.

A preliminary trial of lamivudine for chronic hepatitis B infection.

N Engl J Med 1995; 333: 1657–1661.

Lai

C.L.

, Chien

R.N.

, Leung

N.W.

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

N Engl J Med 1998; 339: 61–68.

Hadziyannis

S.J.

, Tassopoulos

N.C.

, Heathcote

E.J.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

N Engl J Med 2003; 348: 800–807.

Marcellin

, Chang

T.T.

, Lim

S.G.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

N Engl J Med 2003; 348: 808–816.

Lai

C.L.

, Shouval

, Lok

A.S.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

N Engl J Med 2006; 354: 1011–1020.

Chang

T.T.

, Gish

R.G.

, de Man

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

N Engl J Med 2006; 354: 1001–1010.

Marcellin

, Heathcote

E.J.

, Buti

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

N Engl J Med 2008; 359: 2442–2455.

Koike

, Suyama

, Ito

, Itoh

, Sugiura

Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients.

Hepatol Res 2018; 48: 59–68.

10.

Yuen

M.F.

, Sablon

, Hui

C.K.

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

Hepatology 2001; 34: 785–791.

11.

Lok

A.S.

, Lai

C.L.

, Leung

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

Gastroenterology 2003; 125: 1714–1722.

12.

Newbold

J.E.

, Xin

, Tencza

The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes.

J Virol 1995; 69: 3350–3357.

13.

Soriano

, Barreiro

, Benitez

New antivirals for the treatment of chronic hepatitis B.

Expert Opin Investig Drugs 2017; 26: 843–851.

14.

Konerman

M.A.

, Lok

A.S.

Interferon treatment for hepatitis B.

Clin Liver Dis 2016; 20: 645–665.

15.

T.T.

, Coates

, Aldrich

C.E.

, Summers

, Mason

W.S.

In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway.

Virology 1990; 175: 255–261.

16.

Zhou

, Wu

, Wei

A meta-analysis of the efficacy of interferon monotherapy or combined with different nucleos(t)ide analogues for chronic hepatitis B.

Int J Environ Res Public Health 2016; 13: 730–742.

17.

Enomoto

, Tamori

, Nishiguchi

Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential.

J Gastroenterol 2013; 48: 999–1005.

18.

Viganò

, Invernizzi

, Grossi

Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection.

Aliment Pharmacol Ther 2016; 44: 653–661.

19.

Chan

H.L.

, Leung

N.W.

, Hui

A.Y.

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.

Ann Intern Med 2005; 142: 240–250.

20.

Lau

G.K.

, Piratvisuth

, Luo

K.X.

Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

N Engl J Med 2005; 352: 2682–2695.

21.

Wursthorn

, Lutgehetmann

, Dandri

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.

Hepatology 2006; 44: 675–684.

22.

Marcellin

, Ahn

S.H.

, Ma

Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B.

Gastroenterology 2016; 150: 134–144.

23.

Hagiwara

, Kudo

, Osaki

Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.

J Med Virol 2013; 85: 987–995.

24.

Kimura

, Rokuhara

, Sakamoto

Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load.

J Clin Microbiol 2002; 40: 439–445.

25.

Allice

, Cerutti

, Pittaluga

COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma.

J Clin Microbiol 2007; 45: 828–834.

26.

Knodell

R.G.

, Ishak

K.G.

, Black

W.C.

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Hepatology 1981; 1: 431–435.

27.

Ishak

, Baptista

, Bianchi

Histological grading and staging of chronic hepatitis.

J Hepatol 1995; 22: 696–699.

28.

Murata

, Asano

, Matsumoto

Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.

Gut 2018; 67: 362–371.

29.

Sonneveld

M.J.

, Rijckborst

, Boucher

C.A.

, Hansen

B.E.

, Janssen

H.L.

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.

Hepatology 2010; 52: 1251–1257.

30.

, Yang

R.F.

, Wei

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.

J Gastroenterol Hepatol 2010; 25: 1498–1506.

31.

Moucari

, Mackiewicz

, Lada

Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.

Hepatology 2009; 49: 1151–1157.

32.

Marcellin

, Ahn

S.H.

, Chuang

W.L.

Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.

Aliment Pharmacol Ther 2016; 44: 957–966.

33.

Al-Mahtab

, Bazinet

, Vaillant

Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection.

PLoS One 2016; 11: e0156667.

34.

H.Y.

, Zhuang

L.W.

, Yu

Y.Y.

Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients.

World J Gastroenterol 2008; 14: 1268–1273.

35.

Chaudhuri

, Tayal

, Nayak

Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter.

Gastroenterology 2004; 127: 1356–1371.

36.

Suzuki

, Arase

, Akuta

Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan.

J Gastroenterol 2004; 39: 969–974.